Research programme: Alzheimer's disease therapeutics - Crossbeta Biosciences

Drug Profile

Research programme: Alzheimer's disease therapeutics - Crossbeta Biosciences

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Crossbeta Biosciences
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 08 Nov 2016 Crossbeta in-licenses AßO-specific shark antibodies from AdAlta
  • 07 Jul 2016 Preclinical trials in Alzheimer's disease in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top